10/587023 PTO/SB/08a LAP6 Rec'd PCT/PTO 24 JUL 2006 Sheet ATTY, DOCKET NO. INFORMATION DISCLOSURE **CITATION** 620-445 Unknown APPLICANT BERNARDS ET AL. FILING DATE (Use several sheets if necessary) TC/A.U. July 24, 2006 Unknown **U.S. PATENT DOCUMENTS** *EXAMINER FILING DATE INITIAL **DOCUMENT NUMBER** DATE NAME CLASS SUBCLASS IF APPROPRIATE FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY CLASS **SUBCLASS** YES OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Partial International Search Report for PCT/EP2005/000937. Ikeda et al., Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor, Immunity, vol. 6, no. 2, February 1997, pp. 199-208, XP002216277. Plumb et al., Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101, Molecular Cancer Therapeutics, vol. 2, no. 8, August 2003, pp. 721-728, XP002372785. Freemantle et al., Retinoids in cancer therapy and chemoprevention: Promise meets resistance, Oncogene, vol. 22, no. 47, 20 October 2003, pp. 7305-7315, XP008061601. Brummelkamp et al., Stable Suppression of Tumorigenicity by Virus-Mediated RNA Interference, Cancer Cell, vol. 2, no. 3, September 2002, pp. 243-247, XP009006464. Epping et al., The Human Tumor Antigen Prame is a Dominant Repressor of Retinoic Acid Receptor Signaling, Cell, vol. 122, no. 6, 23 September 20045, pp. 835-847, XP008061580, 2005 Tajeddine et al., Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspaseindependent cell death in vitro and reduces tumorigenicity in vivo, Cancer Research, vol. 65, no. 16, August 2005, pp. 7348-7355, XP002372786. Product: sc-37322, Online Catalog of Santa Cruz Biotechnology, Inc., 2004, XP002372787.

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

/Kimberly Chong/

*Examiner

Date Considered

01/20/2011